A double-blind, randomized, placebo-controlled, phase II study of maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following first-line therapy for metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Wolff, R. A.
Schepp, W.
Di Bartolomeo, M.
Hossain, A.
Stoffregen, C.
Nicol, S.
Heinemann, V.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Stadt Klinikum Munchen Klinikum Bogenhausen, Munich, Germany
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Lilly Deutschland GmbH, Bad Homburg, Germany
[6] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, D-80539 Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3527
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3527
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A double-blind, randomized placebo-controlled, phase II study of maintenance enzastaurin (ENZ) with 5-FU/leucovorin (LV) plus bevacizumab (BV) following first-line therapy for metastatic colorectal cancer (mCRC).
    Wolff, R. A.
    Schepp, W.
    DiBartolomeo, M.
    Hossain, A.
    Stoffregen, C.
    Nicol, S.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer
    Wolff, Robert A.
    Fuchs, Martin
    Di Bartolomeo, Maria
    Hossain, Anwar M.
    Stoffregen, Clemens
    Nicol, Steven
    Heinemann, Volker
    CANCER, 2012, 118 (17) : 4132 - 4138
  • [3] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC).
    Kopetz, S.
    Abbruzzese, J. L.
    Eng, C.
    Adinin, R. B.
    Morris, J.
    Wolff, R. A.
    Lin, E.
    Chang, D. Z.
    Hoff, P.
    Bogaard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 165S - 165S
  • [5] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [6] Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Ohtsu, Atsushi
    Shah, Manish A.
    Van Cutsem, Eric
    Rha, Sun Young
    Sawaki, Akira
    Park, Sook Ryun
    Lim, Ho Yeong
    Yamada, Yasuhide
    Wu, Jian
    Langer, Bernd
    Starnawski, Michal
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 3968 - 3976
  • [7] Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
    Raunkilde, Louise
    Hansen, Torben Frostrup
    Havelund, Birgitte Mayland
    Thomsen, Caroline Brenner
    Rafaelsen, Soren Rafael
    Lindebjerg, Jan
    Jensen, Lars Henrik
    ACTA ONCOLOGICA, 2023, 62 (09) : 1066 - 1075
  • [8] BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
    Mettu, Niharika B.
    Niedzwiecki, Donna
    Boland, Patrick Mckay
    Fakih, Marwan
    Arrowood, Christy
    Bolch, Emily
    Hurwitz, Herbert
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] A randomized, double-blind, placebo-controlled, multicenter Phase II clinical trial of fruquintinib in patients with metastatic colorectal cancer (mCRC)
    Li, J.
    Xu, R.
    Bai, Y.
    Xu, J.
    Liu, T.
    Shen, L.
    Wang, L.
    Pan, H.
    Fan, S.
    Hua, Y.
    Su, W.
    Hugg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S366 - S366
  • [10] BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
    Mettu, N. B.
    Twohy, E.
    Ou, F-S.
    Halfdanarson, T. R.
    Lenz, H. J.
    Breakstone, R.
    Boland, P. M.
    Crysler, O.
    Wu, C.
    Grothey, A.
    Nixon, A. B.
    Bolch, E.
    Niedzwiecki, D.
    Fruth, B.
    Schweitzer, B.
    Elsing, A.
    Hurwitz, H.
    Fakih, M. G.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345